A monoclonal antibody targeting amyloid plaques modestly slowed cognitive decline in a phase 3 trial of patients with early Alzheimer's disease.

The absolute benefit was small and accompanied by a meaningful rate of brain swelling and microhaemorrhage detected on imaging, requiring monitoring.

Clinicians remain divided on whether the effect size is clinically meaningful for patients and families.